<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585584</url>
  </required_header>
  <id_info>
    <org_study_id>MISP #39897</org_study_id>
    <secondary_id>24411</secondary_id>
    <nct_id>NCT01585584</nct_id>
  </id_info>
  <brief_title>Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment</brief_title>
  <acronym>LeeG3</acronym>
  <official_title>Triple-Therapy With PegInterferon α-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon α + Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the potential antiviral efficacy of triple-combination
      therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype
      3 who previously failed Peginterferon α + ribavirin (non-responders or relapsers).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      i) Obtain preliminary information on the association between important baseline and
      on-treatment factors and SVR in this patient population. Variables to be examined may
      include gender, age, advanced fibrosis or cirrhosis (F3 or F4 estimated by Fibroscan),
      baseline viral load, RVR, wk 8 viral load, end-of-treatment viral response.

      ii) Evaluate adverse events. iii) Evaluate viral resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Virologic Response (SVR) at 24 Weeks Post Treatment</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained Virologic Response (SVR) is evaluated 24 weeks after end of treatment and defined as undetectable plasma HCV-RNA at follow up week 24. HCV RNA is measured using Cobas TaqMan.Of the 6 subjects who completed the treatment, 3 obtained SVR at 24 weeks post treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Boceprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).</description>
    <arm_group_label>Boceprevir</arm_group_label>
    <other_name>VICTRELIS™</other_name>
    <other_name>boceprevir capsules, 200 mg</other_name>
    <other_name>Hepatitis C Virus (HCV) Protease Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be eligible for the study if they meet the following inclusion
             criteria:

               1. 18 years of age or older

               2. Infected with HCV genotype 3 (mixed genotypes are NOT permitted)

               3. Have received at least 12 weeks of previous treatment with peginterferon-α +
                  ribavirin

               4. Detectable serum HCV-RNA

               5. No significant co-morbid conditions

               6. Liver biopsy is not necessary

               7. Cirrhotic patients will be eligible to participate if Child-Pugh class A
                  (maximum 15% of subjects)

        Exclusion Criteria:

          -  Subjects will be excluded from participation in this study if the following
             conditions are present:

               1. Significant comorbidities: uncontrolled psychiatric conditions including severe
                  depression, cardiovascular, respiratory, renal or metabolic conditions, active
                  carcinoma.

               2. Active substance abuse within the past 12 months

               3. Co-infection with hepatitis B or HIV

               4. Decompensated cirrhosis (Child-Pugh class B or C)

               5. Significant cytopenia - any of the following: platelets &lt;80 x 109/L, neutropenia
                  &lt;1.2 x 103/L, Hb &lt;120 g/l for men or 110 g/l for women

               6. Lack of informed consent

               7. Previous null-responders (&lt;2 log10 decrease at week 12 with previous PR therapy)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary Liver Unit</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 22, 2015</lastchanged_date>
  <firstreceived_date>April 18, 2012</firstreceived_date>
  <firstreceived_results_date>August 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Sam Lee</investigator_full_name>
    <investigator_title>Hepatologist</investigator_title>
  </responsible_party>
  <keyword>Boceprevir</keyword>
  <keyword>Hepatitis C Genotype 3</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
